Erratum {#Sec1}
=======

After publication of the original article \[[@CR1]\], the author noticed that there are some error with Table [2](#Tab1){ref-type="table"} and Table [3](#Tab2){ref-type="table"}. Please see the correct Tables below. We apologize for any inconvenience caused.Table 2CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patientsCharacteristicsPatients, N (%)Median survival (months)5-year survival (%)PCXCL16 Cancer cells.080  High48 (14)NR67  Low227 (68)9856  Missing60 (18) Stromal cells**.016**  High258 (77)18962  Low43 (13)5748  Missing34 (10)CXCR6 Cancer cells.093  High41 (12)19073  Low245 (73)12255  Missing49 (15)CXCL16 Cancer cells + stromal cells combined**.016**  High/High43 (13)NR71  High/Low182 (54)19058  Low/Low41 (12)4748  Missing69 (21)NR, not reached; NCSLC, non-small cell lung cancer. Bold values indicate p \< 0.05 Table 3Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2\*)FactorHRCI 95%PT-status**\<0.001** ^**†**^ T11.00 T21.60(0.97-2.64)0.065 T33.80(2.13-6.77)**\<0.001**N-status**\<0.001** ^**†**^ N01.00 N12.01(1.30-3.11)**0.002** N23.08(1.74-5.44)**\<0.001**Differentiation**0.009** ^**†**^ Well1.00 Moderate1.17(0.63-2.20)0.618 Poor2.08(1.12-3.85)**0.020**Performance status**0.040** ^**†**^ ECOG 01.00 ECOG 11.52(1.02-2.26)**0.040** ECOG 22.15(0.94-4.91)0.069Vascular infiltration No1.00 Yes1.70(1.01-2.87)**0.046**Histology**\<0.001** ^**†**^ Squamous carcinoma1.00 Adenocarcinoma2.23(1.48-3.35)**\<0.001** Large cell carcinoma0.80(0.39-1.66)0.555CXC16 stromal cells Low1 High0.55(0.35-0.87)**0.011**CXCL16 cancer and stromal cells\***0.031** ^**†**^ Low/Low1.00 Low/High + High/Low0.57(0.35-0.93)**0.023** High/High0.42(0.20-0.88)**0.022**^†^Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p \< 0.05

The online version of the original article can be found under doi:10.1186/s12885-015-1446-z.
